CTTQ-Akeso
CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. (CTTQ-Akeso), with registered capital of RMB 690 million, is an innovative biomedical company jointly established by Akeso, Inc. (9926.HK) and Chia Tai Tianqing Pharmaceutical Group Co., Ltd... CTTQ-Akeso focuses on the R&D of innovative biologics, industrialization of research results, technology transfer and commission processing, and is committed to the R&D and commercialization of the anti PD-1 monoclonal antibody drug Penpulimab monoclonal antibody injection (安尼可?) for tumor immunotherapy.
?
In April 2023，CTTQ-Akesoentered into a partnership agreement with Specialised Therapeutics （ST）to commercialise 安尼可? in Australia, New Zealand, Papua New Guinea and 11 countries in Southeast Asia including Singapore and Malaysia.The total consideration for the cooperation amounts to approximately US$73 million, and CTTQ-Akeso shall be entitled to a double-digit commission on the net sales of the drug in authorized regions.Through differentiated advantages of 安尼可??，the partnership will robust its market presence in Southeast Asia and has become a powerful extension and supplement of the company's commercialization system in overseas markets.
安尼可? (Penpulimab injection)
At present, 安尼可? is the only PD-1 monoclonal antibody that applies the immunoglobulin G1 (‘‘IgG1’’) subtype modified by the fragment crystallizable (Fc) segment in the world, which has a lower antigen binding off-rate and a unique binding epitope as demonstrated by analysis on crystal structure. These features allow 安尼可? to effectively and continuously block PD-1/PD-L1 binding, thus differentiating it from PD-1 products on the market, and may enable安尼可? to more effectively enhance immunotherapeutic efficacy and reduce immune-related adverse reactions. The main indications for安尼可? include lung cancer, liver cancer, gastric cancer, nasopharyngeal cancer, esophageal cancer, classical Hodgkin’s lymphoma, mesothelioma, thymic cancer, urothelial cancer, bile duct cancer and neuroendocrine cancer. Currently, ?phase III clinical studies on 安尼可? plus Anlotinib in the first-line treatment of non-phosphorous non-small cell lung cancer, liver cancer and gastric cancer, have all entered the final stage.
Milestones for安尼可?
Fenglin Building, No.420 Fenglin Road, Xuhui District, Shanghai
400-008-5183 (working days: 9:00–17:00)
Note: If your report involves an adverse event of CTTQ-Akeso’s products, the relevant patient information and data will be disclosed to CTTQ-Akeso’s pharmacovigilance department in accordance with the applicable laws and regulations, and the relevant personnel may follow up with you on the adverse event. The information will be input into CTTQ-Akeso’s drug safety database and may be legally required to reported to relevant regulatory departments.